Skip to main content
SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. logo

SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. — Investor Relations & Filings

Ticker · 688238 ISIN · CNE1000059N9 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 482 across all filing types
Latest filing 2025-05-08 Major Shareholding Noti…
Country CN China
Listing Shanghai Stock Exchange 688238

About SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD.

https://www.obio-tech.com/

SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. is a specialized Contract Development and Manufacturing Organization (CDMO) focused on the gene and cell therapy (GCT) sector. The company provides end-to-end solutions encompassing vector construction, process development, analytical method development, and large-scale GMP manufacturing. Its service portfolio includes the production of viral vectors such as adeno-associated virus (AAV), lentivirus, adenovirus, and oncolytic viruses, as well as plasmid DNA and cell therapy products. Obio Technology supports clients from early-stage research through clinical trials to commercialization. The company operates advanced facilities designed to meet international regulatory standards, facilitating the development of innovative genetic medicines and advanced therapies for global biopharmaceutical partners.

Recent filings

Filing Released Lang Actions
股东减持股份计划公告
Major Shareholding Notification Classification · 100% confidence The document is a detailed announcement regarding a shareholder's plan to reduce their holdings in the company. It includes specifics about the shareholders involved, the number and percentage of shares to be reduced, the methods of reduction (such as centralized bidding and block trades), the timing of the reduction, and compliance with relevant securities laws and stock exchange regulations. There is no financial data, earnings information, or management discussion of financial results. The document is not a report or presentation but a formal disclosure of a planned transaction by shareholders. This fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels.
2025-05-08 Chinese
2024年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement of the resolutions passed at the 2024 Annual General Meeting (AGM) of 和元生物技术（上海）股份有限公司. It details the meeting date, attendance, voting results on various proposals including the 2024 annual report, board work report, financial reports, profit distribution, auditor appointment, and other governance matters. The document is a formal disclosure of voting results and meeting proceedings rather than the full annual report or financial statements themselves. The length is about 4506 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2025-05-08 Chinese
国泰海通证券股份有限公司关于和元生物技术（上海）股份有限公司2024年度持续督导跟踪报告
Annual Report Classification · 95% confidence The document is titled as a "2024年度持续督导年度跟踪报告" which translates to "2024 Annual Continuous Supervision Follow-up Report" by the sponsor institution for a listed company. It contains detailed financial data for the year 2024, including revenue, net profit, and other financial indicators, as well as extensive discussion of business risks, core competitiveness, R&D progress, and supervisory activities. The document is comprehensive and includes substantive financial data and analysis for a full fiscal year. It is not a brief announcement or a certification letter but a detailed report on the company's performance and supervision during the year. This matches the characteristics of an Annual Report (10-K) type document, which covers company activity and full financial performance for the year. Therefore, the appropriate classification is Annual Report (10-K). FY 2024
2025-04-28 Chinese
2024年年度股东大会会议资料
AGM Information Classification · 100% confidence The document is titled as "2024 年年度股东大会 会议资料" which translates to "2024 Annual General Meeting (AGM) Meeting Materials". It contains detailed agenda items, meeting instructions, and multiple proposals to be voted on during the 2024 Annual General Meeting of 和元生物技术（上海）股份有限公司 (OBiO Technology (Shanghai) Corp., Ltd.). The content includes meeting procedures, voting instructions, and summaries of reports such as the 2024 Annual Report, Board of Directors report, Supervisory Board report, financial statements, profit distribution plan, audit firm appointment, and other governance matters. The document is clearly the presentation and materials shared during the AGM, not the actual annual report or other filings themselves. It is comprehensive and well over 5,000 characters, so it is not a mere announcement of a report publication. Therefore, the document fits the category of AGM Information (AGM-R).
2025-04-25 Chinese
2025年第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "和元生物技术（上海）股份有限公司2025 年第一季度报告" which translates to "Heyuan Biotechnology (Shanghai) Co., Ltd. 2025 First Quarter Report." It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on financial performance for the first quarter of 2025. The document explicitly states it is a quarterly report and includes unaudited financial statements for the quarter ending March 31, 2025. It also includes management commentary on financial results and business operations during the quarter. The length of the document (15,000 characters) and the presence of substantive financial data confirm it is a full interim/quarterly financial report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2025
2025-04-23 Chinese
国泰海通证券股份有限公司关于和元生物技术（上海）股份有限公司2024年度持续督导工作现场检查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2024年度持续督导工作现场检查报告" which translates to "2024 Annual Continuous Supervision On-site Inspection Report" by the sponsor Guotai Huatong Securities Co., Ltd. for Heyuan Biotechnology (Shanghai) Co., Ltd. It details the sponsor's on-site inspection activities during the continuous supervision period, including governance, internal controls, information disclosure, independence, related party transactions, use of raised funds, guarantees, major investments, and operating conditions. The document includes detailed findings and opinions from the sponsor but does not present full financial statements or comprehensive financial performance data typical of an Annual Report (10-K) or Interim Report (IR). It is a standalone audit/supervision report related to regulatory compliance and sponsor oversight, fitting the definition of an Audit Report / Information (AR). The document length is 3671 characters, which is not extremely short, and it contains substantive content rather than just an announcement or certification. Therefore, the best classification is AR with high confidence. FY 2024
2025-04-23 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.